RxDoctor Payments Data

Ram Belbase, MD

Interventional Cardiology · Gastonia, NCNPI 1750539169

Payments from drug & device makers

$5,117in general payments, 2019–2025

Across 67 payments — averaging $76.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abiomed$779
  • Abbott$358
  • Heartflow, Inc.$193
  • Inari Medical, Inc.$160
  • Chiesi USA, Inc.$120
  • plus $464 from 13 others

What the payments were for

  • Travel & lodging$1,99039%
  • Food & beverage$3,11561%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,117 in reported general payments places this provider in the 35th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$140,680
Medicare patients
570
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$146,826
JardianceEmpagliflozin43$40,783
EntrestoSacubitril/Valsartan20$26,266
BrilintaTicagrelor17$7,403
Metoprolol Succinate199$1,670
Atorvastatin Calcium134$1,190
Losartan Potassium142$1,133
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,037
Rosuvastatin Calcium32$910
Ezetimibe52$885
ClopidogrelClopidogrel Bisulfate90$782
Isosorbide Mononitrate ErIsosorbide Mononitrate107$745
Furosemide150$561
Metoprolol Tartrate111$558
Amlodipine Besylate106$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$146,826176 claims
Boehringer IngelheimJardiance$14$40,78343 claims
NovartisEntresto$16$26,26620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →